Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1464

1.
2.
3.
5.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
6.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
7.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
8.
9.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
10.

Varenicline for smoking cessation: a placebo-controlled, randomized study.

Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S.

Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20.

PMID:
19192221
11.

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Keating GM, Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Review.

PMID:
20108995
12.

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.

West R, Baker CL, Cappelleri JC, Bushmakin AG.

Psychopharmacology (Berl). 2008 Apr;197(3):371-7. Epub 2007 Dec 15.

PMID:
18084743
13.

Varenicline: a novel pharmacotherapy for smoking cessation.

Jiménez-Ruiz C, Berlin I, Hering T.

Drugs. 2009 Jul 9;69(10):1319-38. doi: 10.2165/00003495-200969100-00003. Review.

PMID:
19583451
14.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
15.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.

PMID:
16820547
16.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
17.

Varenicline: a review of its use as an aid to smoking cessation therapy.

Keating GM, Siddiqui MA.

CNS Drugs. 2006;20(11):945-60. Review.

PMID:
17044731
18.

Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.

Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, Park PW, Chopra P.

Clin Ther. 2011 Apr;33(4):465-77. doi: 10.1016/j.clinthera.2011.04.013.

PMID:
21635992
19.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J.

Curr Med Res Opin. 2007 Apr;23(4):793-801.

PMID:
17407636
20.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
Items per page

Supplemental Content

Write to the Help Desk